Quality Of Life (Qol) And Clinical Outcomes Of Dasatinib Treatment In Tki-Naive And Early Switched From Imatinib Patients With Chronic Myeloid Leukemia In Chronic Phase (Cp Cml) In A Real World Setting

Tatyana Ionova,Natalia Bulieva,Olga Vinogradova,Kira Kurbatova,Elza Lomaia,Tatyana Nikitina,Natalia Novitskaya, Anna Rodionova,Elena Usacheva, Marina Chukavina, Marina Shumkova

BLOOD（2016）

引用 0|浏览6

暂无评分

摘要

Dasatinib as a front-line is a promising treatment option for CP-CML pts. Assessment of benefits and risks of this treatment regimen both from physician's and patient's perspective sounds worthy. We aimed to study QoL and clinical outcomes of dasatinib as a front-line treatment in CP CML pts in a real world setting.

查看译文

关键词

chronic myeloid leukemia,imatinib patients,dasatinib treatment,clinical outcomes,tki-naive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要